Biogen 3.09 Rise Driven by Strong Q2 Results and Alzheimer s Sales as 360M Volume Ranks 354th

Biogen Inc. (NASDAQ:BIIB) rose 3.09% on August 1, 2025, with a trading volume of $360 million, ranking 354th in market activity. The stock’s performance followed a series of positive developments, including stronger-than-expected Q2 results and elevated full-year profit guidance. Management attributed the growth to robust sales of Alzheimer’s therapy Leqembi and rare disease treatments, which offset declines in older multiple sclerosis (MS) products.

Analysts upgraded price targets, reflecting optimism about Biogen’s near-term outlook. Royal Bank of Canada raised its target to $219 from $208, while HC Wainwright increased its estimate to $194 from $187, both maintaining “Outperform” or “Buy” ratings. Citi also raised its target, citing strong core product sales. However, some caution persisted, with Morgan Stanley cutting its target to $144 and Bank of America lowering its price objective to $142, reflecting concerns over modest growth and pipeline uncertainties.

Positive momentum was further fueled by long-term data supporting Biogen’s Alzheimer’s pipeline. Eisai/Biogen and Eli Lilly presented updated results on Leqembi and other therapies, reinforcing confidence in the drug’s durability. A two-year real-world study of Leqembi in the U.S., presented at the Alzheimer’s Association International Conference, showed sustained benefits for early-stage patients, bolstering demand expectations.

A backtest of a liquidity-driven trading strategy showed that buying the top 500 high-volume stocks and holding for one day generated a 166.71% return from 2022 to 2025, far outperforming the 29.18% benchmark. This highlights the role of liquidity concentration in short-term stock performance, particularly in markets with rapid volume shifts.